(USD) | Dec 2023 | Q/Q |
---|---|---|
Revenue | 61MM | +22% |
Gross Profit | 41.7MM | - |
Cost Of Revenue | 19.3MM | +25% |
Operating Income | -8.6MM | -36% |
Operating Expenses | 50.4MM | - |
Net Income | -11.8MM | -30% |
R&D | - | - |
G&A | 43.1MM | -1% |
Amortization | 1.1MM | +1% |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
NEWPORT BEACH, Calif., March 26, 2024--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio, today announced that members of its management team will present at the following investor conference in April:
In this article, we will take a detailed look at the 10 Stocks George Soros and Insiders Are Crazy About. For a quick overview of such stocks, read our article 5 Stocks George Soros and Insiders Are Crazy About. The strange calm in the US stock markets following the latest hotter-than-expected CPI report has analysts scratching their heads. Many […]
The consensus price target hints at a 63.2% upside potential for Evolus, Inc. (EOLS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
NEWPORT BEACH, Calif., March 11, 2024--Evolus, Inc. (Nasdaq: EOLS) announced today the pricing of its underwritten offering of 3,554,000 shares of its common stock at a underwritten offering price of $14.07 per share, which is equal to the closing price on Friday, March 8, 2024, before underwriting discounts and commissions. The gross proceeds from the offering to Evolus are expected to be approximately $50.0 million, before deducting underwriting discounts and commissions and offering expenses.
Last week, you might have seen that Evolus, Inc. ( NASDAQ:EOLS ) released its yearly result to the market. The early...
Evolus ( NASDAQ:EOLS ) Full Year 2023 Results Key Financial Results Revenue: US$202.1m (up 36% from FY 2022). Net loss...
NEWPORT BEACH, Calif., March 08, 2024--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant of non-qualified stock options to purchase an aggregate of 11,355 shares of Evolus and an aggregate of 82,730 restricted stock units (RSUs) of the company’s common stock to 8 newly hired non-executive employees of the company. The awards were approved by the compensation committee of the company’s board of di
Evolus, Inc. (NASDAQ:EOLS) Q4 2023 Earnings Call Transcript March 7, 2024 Evolus, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good afternoon, everyone, and thank you for standing by. Welcome to Evolus’ Fourth Quarter and Full Year 2023 Earnings […]
Q4 2023 Evolus Inc Earnings Call
Key Financial Highlights from Evolus Inc's Latest Earnings Release